ORIC PHARMACEUTICALS, INC. Other Non-Current Assets
ORIC PHARMACEUTICALS, INC. (ORIC) had Other Non-Current Assets of $5.95 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2026-08-03
- 2026-06-30: Other Assets, Noncurrent $5.95M.
- 2026-03-31: Other Assets, Noncurrent $6.60M.
- 2025-12-31: Other Assets, Noncurrent $7.25M.
- 2025-09-30: Other Assets, Noncurrent $7.13M.
| Period end | Other Assets, Noncurrent | Other Assets, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $5.95M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $6.60M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $7.25M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $7.13M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $7.75M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $8.37M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $8.97M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $9.55M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $9.30M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $9.21M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $9.70M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $10.17M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $10.63M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $11.06M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $11.52M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $11.95M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $12.38M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $11.94M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $12.32M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $12.55M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $1.45M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $1.89M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $319.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $711.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $319.00K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $317.00K 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $1.85M 10-K · filed 2021-03-23 | $510.00K 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |